The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Updates for 2025 in the field of clonal hematopoiesis
In this interview, David Steensma, MD, Ajax Therapeutics, New York, NY, briefly outlines recent updates in the field of clonal hematopoiesis, noting that these developments have expanded the understanding of this precursor condition. Dr Steensma mentions the discovery of tumor-infiltrating clonal hematopoiesis as a risk factor for recurrence in non-myeloid tumors, expressing his excitement at this recent development. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Clonal hematopoiesis and somatic mosaicism more broadly really continues to be a very active and vibrant area of investigation as we learn more about how genetic changes occur over the course of life and what sort of health conditions that those predispose to and interact with. Some of the more recent developments, in addition to refining risk scores for predicting outcomes in patients with clonal hematopoiesis, include the discovery that tumor-infiltrating clonal hematopoiesis is a risk factor for recurrence in non-myeloid tumors...
Clonal hematopoiesis and somatic mosaicism more broadly really continues to be a very active and vibrant area of investigation as we learn more about how genetic changes occur over the course of life and what sort of health conditions that those predispose to and interact with. Some of the more recent developments, in addition to refining risk scores for predicting outcomes in patients with clonal hematopoiesis, include the discovery that tumor-infiltrating clonal hematopoiesis is a risk factor for recurrence in non-myeloid tumors. So that was an exciting development. We’ve also learned more about in mouse models, just how these clones evolve and what some of the drivers of those are. In addition, there are an increasing number, ever increasing number, of driver mutations associated with clonal hematopoiesis. So really a lot going on in this field.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Employment: Ajax Therapeutics.
